Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Oxford have begun screening participants in DPUK’s Deep and Frequent Phenotyping (DFP) study – the world’s most detailed study into early Alzheimer’s disease.

First participant arrives for screening as part of Deep and Frequent Phenotyping study
Study volunteer Gillian Brown talks to DFP trial co-ordinator Dr Tony Thayanandan

Launched last month, the DFP study is jointly funded by the MRC and NIHR, and aims to tackle the challenge of diagnosing and tracking Alzheimer’s disease in its earliest stages – often decades before symptoms start to show.

DFP will recruit 250 participants from across the UK who are over 60 and in good health, but with a family history of dementia. Volunteers will undergo a range of existing and novel tests over a year-long period, including brain scans, cognitive and memory tests, scans of brain magnetic fields, retinal imaging, blood tests, and the use of wearable technology to measure movement, gait and ongoing cognitive abilities.

This will be the most comprehensive set of assessments ever completed in this group of people. Data from the study will be made available to researchers via the secure DPUK Data Portal.

Read more (Dementias Platform UK website)

Similar stories

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.

RECOVERY Trial paper wins BMJ’s 2021 UK Research Paper of the Year Award

For the second year in a row, The British Medical Journal have selected a publication co-authored by Oxford University researchers for their prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare.

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.